Bivona Lab

Our latest paper is out now in @NatureGenetics! We investigate how APOBEC3B affects EGFR mutant non-small cell lung cancer evolution, from tumor initiation to targeted therapy resistance. nature.com/articles/s4158…

Join the @BivonaLabUCSF team at #AACR25 Chicago on April 29th! @Tadashi_Manabe 2:30-4:00 PM, Minisymposium Room S102 @YTChou 2:00-5:00 PM, Poster Section 18 Nilanjana Chatterjee 2:00-5:00 PM, Poster Section 17 Stop by to discuss our latest research findings! @UCSFCancer @UCSF

Dr. Trever Bivona @BivonaLabUCSF presents on the progress of the BAATAAR-UP Center, which focuses on acquired resistance in lung cancer. #ARTNetAnnual

Pleased to report the results of our clinical trial: Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung #JCO #EGFR ascopubs.org/doi/10.1200/JC… Thank you to all of the patients who participated.

Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer | @BivonaLabUCSF @roose_jeroen @UCSF via @NatureComms pubmed.ncbi.nlm.nih.gov/38702301/

Just out in @NatureComms! Drs. Trever Bivona @BivonaLabUCSF, Jack Roth @JackARothMD and team uncover how the FAK-YAP signaling axis drives drug-tolerant cells and residual disease in lung cancer. #lungcancer #cancerresearch #ARTNetPublication 👇 pubmed.ncbi.nlm.nih.gov/38702301/

Just released on @NatureCancer: "PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors in myeloma and breast cancer in both pre-clinical and clinical models." Congrats to @BivonaLabUCSF! t.ly/ASZ8p

Members of the Bivona lab at #AACR24 last week!

Thanks @CD_AACR for highlighting our work showing the complex and context dependant effect of APOBEC3B on lung tumor evolution and targeted cancer therapy resistance! aacrjournals.org/cdnews/news/12…

In an international collaboration between @bivonaLabUCSF and @HarrisLabUTHSA in the USA and @Drmcaswell @SwantonLab and #DownwardLab at the Crick, researchers found that the mutagenic enzyme APOBEC3B can contribute to targeted cancer therapy resistance nature.com/articles/s4158…

Very proud to have this work finally out in @NatureGenetics! This was a wonderful team effort; I would like to thank Manasi Mayekar and @BivonaLabUCSF. It was a privilege to work with our collaborators @drmcaswell and @CharlesSwanton from @TheCrick!

I am excited to announce the publication of our manuscript out today, with @DrPhilippeGui, @CharlesSwanton, @SwantonLab, @BivonaLabUCSF, @Downwardlab, and @HarrisLabUTHSA! 🧵 1/15 nature.com/articles/s4158…

This Friday, June 2 @UCSF Cancer Research Seminar | Silvio Gutkind, PhD @UCSDCancer @SilvioGutkind "Exploiting Cancer Signaling Circuitries in the Era of Precision Medicine: Novel Multimodal Targeted and Immunotherapies" Hosted by @BivonaLabUCSF ow.ly/7vXH50OuCrw

Finally this preprint! We describe functional ATM deficiency in Ewing sarcoma, a famously chemo-sensitive tumor, and link to native FET protein biology in DNA repair. Led by stellar postdoc @Shruti_menon09, in collab w/ @BivonaLabUCSF @SweetCorderoLab. biorxiv.org/content/10.110…

Excited to learn from all the innovation at #AACR2023 We describe T-cell clonal expansion and tumor neoantigens in lung cancer as a potential clinical frontier - learn more at our poster session! section 21: abstract #605 @BivonaLabUCSF @UCSFHospitals #immunology #CancerResearch

Happy holidays from the Bivona lab! 🎄🎅

Saying farewell and wishing the all the best to @TulpuleLab for the next step of his career at @MSKCancerCenter! Looking forward to more great science!

Check out our abstract and poster EP08.02-217 Grateful for my mentor @collin_blakely , teammates @DanielLucasKerr and advocates @LAGurwitch @IASLC

Please checkout the updated version of our preprint, a result of a great collaboration with ⁦@BivonaLabUCSF @HarrisLabUMN with my mentors @CharlesSwanton and⁩ @JulianDownward. Work done @TheCrick @SwantonLab #Downwardlab biorxiv.org/content/10.110…